Full Generic Medicine Info
Dosage/Direction for Use

Adult: Initially, 40-80 mg once daily, increased wkly to ≥240 mg/day according to response.
Elderly: Initially, 20 mg/day. Titrate according to response.
Renal impairment: May require lower dose or less frequent admin.
CrCl (ml/min)Dosage Recommendation
<10Give every 40-60 hr.
10-30Give every 24-48 hr.
31-50Give every 24-36 hr.

Angina pectoris
Adult: Initially, 40 mg once daily, increased wkly up to 160 mg/day depending on response. Max: 240 mg/day.
Renal impairment: May require lower dose or less frequent admin.
CrCl (ml/min)Dosage Recommendation
<10Give every 40-60 hr.
10-30Give every 24-48 hr.
31-50Give every 24-36 hr.

Cardiac arrhythmias
Adult: 40-160 mg once daily.

Prophylaxis of migraine
Adult: 40-160 mg once daily.

Adjunct in hyperthyroidism
Adult: 80-160 mg once daily. May require higher doses depending on patient's response.
May be taken with or without food.
AV block (2nd and 3rd degree), sinus bradycardia, bronchial asthma, cardiogenic shock, or overt cardiac failure.
Special Precautions
Inadequate cardiac function, latent cardiac insufficiency, well-compensated heart failure, nonallergic bronchospasm, DM, myasthenia gravis, peripheral vascular disease including Raynaud's disease. Patients undergoing surgery involving general anaesth. Renal or hepatic impairment. May mask signs and symptoms of hyperthyroidism and acute hypoglycaemia. Avoid abrupt withdrawal as it may precipitate thyroid storm, exacerbate angina, HTN and MI. Pregnancy and lactation. Monitoring Parameters Monitor heart rate and BP. Carefully monitor signs/symptoms of angina exacerbation when discontinuing therapy.
Adverse Reactions
Dizziness, fatigue, hallucinations, mental depression, sedation, headache, paraesthesia, malaise, insomnia, sleep disturbances. Bradycardia, peripheral vascular insufficiency, GI disturbances (e.g. diarrhoea, nausea, vomiting). Bronchospasm, rash, pruritus, reversible alopecia, slurred speech, dry mouth, eyes and skin, facial swelling, wt gain, impotence, nasal stuffiness, tinnitus, cough, blurred vision, weakness, sweating, numbness and atypical behaviour.
Symptoms: Hypotension, bradycardia, bronchospasm, acute cardiac failure. Management: If ingestion is recent, emesis should be induced. Endotracheal intubation followed by gastric lavage w/ activated charcoal should be performed if patient is comatose, having seizures or lacks gag reflex. IV atropine sulfate may be given for excessive bradycardia, and if it persists, IV isoproterenol HCl may be administered cautiously. For hypotension, a vasopressor (e.g. dobutamine, dopamine, epinephrine, norepinephrine) may be given cautiously, and for bronchospasm, a β2-adrenergic agonist and/or IV aminophylline. An IV cardiac glycoside and diuretic may be used for cardiac failure. IV glucagon may also be useful. Haemodialysis may be beneficial in severe cases.
Drug Interactions
Antagonises β-adrenergic stimulating effects of sympathomimetic agents (e.g. isoproterenol). Additive hypotensive effects w/ diuretics or other hypotensive drugs, phenothiazines, reserpine. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. May potentiate and prolong the effects of neuromuscular blockers (e.g. tubocurarine Cl). Reduced antihypertensive effects w/ NSAIDs.
Nadolol is a non-cardioselective β-blocker. It lacks intrinsic sympathomimetic and membrane-stabilising activity.
Duration: 17-24 hr.
Absorption: Incompletely absorbed from the GI tract. Time to peak plasma concentration: Approx 3 or 4 hr.
Distribution: Widely distributed and enters breast milk. Volume of distribution: Approx 2 L/kg. Plasma protein binding: Approx 30%.
Metabolism: Not metabolised.
Excretion: Via urine (as unchanged drug). Plasma half-life: Approx 12-24 hr.
Oral: Store between 15-30°C. Avoid excessive heat. Protect from light.
CIMS Class
ATC Classification
C07AA12 - nadolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on nadolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in